Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Teva Branded Pharmaceutical Products R&D
EIR
•Teva Branded Pharmaceutical Products R&D•June 30, 2016

Teva Branded Pharmaceutical Products R&D – FDA EIR, Jun 30, 2016

Record Details

An FDA surveillance inspection of Teva Pharmaceuticals' corporate headquarters in Horsham, PA was conducted from June 8 to June 30, 2016. This unannounced inspection, operating under CPG 7353.001 for Postmarketing Adverse Drug Experience (PADE) reporting regulations, primarily focused on the company's systems for handling complaints and post-market adverse drug events.The inspection revealed several significant issues, leading to the issuance of a 6-item FDA Form 483. Main violations included the lack of documented written procedures for the receipt and reporting of postmarketing adverse drug experiences, and a failure to report all serious and unexpected adverse drug experiences to the FDA within the required 15 calendar days. Additionally, Teva was cited for not submitting quarterly periodic adverse drug experience reports and nonprescription drug adverse event reports within their respective deadlines. Deficiencies were also noted within the quality control unit, where written procedures were not reviewed or approved, and unit responsibilities were not consistently followed.Further discussions highlighted concerns about the absence of a mechanism to verify the delivery of adverse event follow-up letters, a significant delay in recalling the Zecuity product despite numerous burn complaints, and inadequate staffing contributing to late report submissions. Teva Pharmaceuticals submitted a written response to the FDA's observations on July 21, 2016, outlining its planned corrective actions.

Company
Teva Branded Pharmaceutical Products R&D
Inspection date
June 30, 2016
Product type
drugs
Office
Philadelphia District Office
People
  • Joseph De Vito (company_representative)
  • Gerard Greco (company_representative)
  • Tai Kleinfeld (company_representative)
  • Craig D. Zagata (Investigator)
  • Kenneth P. Lavin (company_representative)
View Company Profile

ID · 1a8af15c-f8f5-442f-94e9-23f25c67d655

Violation Codes10
21 CFR 314.80(c)(2)21 CFR 211.100(a)FD&C Act 760(c)(1)21 CFR 820.19821.U.S.C. 355(a)21 CFR 21121 CFR 314.80(c)(1)(i)FD&C Act 505(a)21 CFR 314.80(b)21 CFR 211.22(d)

Full citation text and observation details available on the Dashboard.

Other documents for Teva Branded Pharmaceutical Products R&D
  • 483 - 2016-06-30June 30, 2016

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Teva Branded Pharmaceutical Products R&D
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.